Lisata Therapeutics Partners with Catalent for ADC Innovation
Catalent acquires global rights to explore certepetide and its derivatives as SMARTag payloads for a new range of antibody-drug conjugates (ADCs) targeting challenging diseases.
This collaboration marks a significant step in improving treatment options for patients with advanced solid tumors by leveraging the unique properties of certepetide. Preclinical studies hint at a promising future for these therapies, aiming at boosting their effectiveness against hard-to-treat conditions.
Lisata Therapeutics, a clinical-stage pharmaceutical company, stands at the forefront of developing groundbreaking treatments. The agreement grants Catalent the freedom to integrate Lisata's certepetide into its innovative SMARTag technology, which is designed to enhance the delivery of therapies to tumors. As an internalizing RGD cyclic peptide, certepetide positions itself as an agent that can boost the effectiveness of concurrent cancer treatments.
Through this agreement, Catalent holds non-exclusive, worldwide rights to create bioconjugate products incorporating certepetide. This empowers Catalent to collaborate with other entities, opening doors for potentially groundbreaking advancements. The partnership could yield over $10 million in tiered payments from Lisata, alongside revenue sharing from future sales.
“We are thrilled to collaborate with Catalent,” stated Kristen K. Buck, M.D., Executive Vice President of Research and Development and Chief Medical Officer at Lisata. “This agreement showcases our shared confidence in the potential of certepetide and advances Lisata’s mission to provide transformative therapies. Catalent’s resources and innovative strategies complement certepetide’s unique biology perfectly.” This sentiment reflects Lisata’s resolute pursuit of improving patient outcomes through scientific advancement.
Catalent is eager to unlock the potential of iRGD biology within ADCs. Initial data suggests that incorporating iRGD peptides can considerably enhance the efficacy and pharmacokinetic profiles of these drug conjugates, paving the way for new therapeutic possibilities.
About Lisata Therapeutics
Lisata Therapeutics specializes in developing and commercializing innovative therapies for treating advanced solid tumors and severe diseases. They prioritize creating effective solutions, and their cyclic peptide candidate, certepetide, showcases the company’s commitment to improving cancer treatment through innovative methods. The unique properties of certepetide enable a specific uptake mechanism that allows it to work in conjunction with other anti-cancer treatments, increasing their efficacy.
Lisata has created significant collaborations in research and development, reinforcing its dedication to developing potential drug therapies. With the milestone events on the horizon, the company expects that its available capital will sustain its operations while achieving critical data benchmarks through ongoing and future clinical trials.
Understanding Certepetide
Certepetide, an innovative cyclic peptide candidate, aims to improve cancer treatment by enhancing the uptake of co-administered therapies into solid tumors. This compound triggers an active transport system unique to tumor environments, facilitating better penetration of anti-cancer drugs and modifying the tumor microenvironment, which can make it more receptive to immunotherapies.
Lisata is pushing the boundaries of current treatment modalities by exploring how certepetide can help these therapies work more effectively against various solid tumors. With favorable safety and efficacy data emerging from clinical trials, the future looks promising for this investigational treatment. Certepetide’s achievements include Fast Track and Orphan Drug Designations, highlighting its potential and importance in cancer therapy.
About Catalent
Catalent, Inc. holds a leadership role in the global contract development and manufacturing space, working closely with pharmaceutical, biotechnology, and consumer health companies to improve treatment availability. Their mission revolves around providing cutting-edge solutions that enhance patient health worldwide, utilizing vast scientific resources and advanced technology.
They actively support product development across all phases, ensuring that innovative therapies reach those in need. Catalent launches numerous new products each year, demonstrating their commitment to enhancing health outcomes through scientific advancement.
Frequently Asked Questions
1. What is the significance of the agreement between Lisata and Catalent?
The agreement enables Catalent to incorporate Lisata's certepetide into their ADCs, potentially improving treatment options for cancer patients.
2. How does certepetide work in cancer treatment?
Certepetide enhances the delivery of anti-cancer drugs to tumors, improving their effectiveness and making them more susceptible to treatment.
3. What designations has certepetide received?
Certepetide has received Fast Track and Orphan Drug Designations for pancreatic cancer in both the U.S. and E.U., along with designations for glioma and osteosarcoma.
4. How do Lisata and Catalent plan to develop their collaboration?
They aim to leverage Catalent's SMARTag technology and positive preclinical results to develop novel treatment options targeting hard-to-treat diseases.
5. Will Lisata announce more milestones soon?
Yes, Lisata expects to reveal multiple milestones related to their ongoing trials and partnerships in the coming months.
